# Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED

> **NCT07412860** · NA · RECRUITING · sponsor: **FB Vision S.p.A** · enrollment: 74 (estimated)

## Conditions studied

- Dry Eye Syndromes
- Dry Eye Disease (DED)

## Interventions

- **DEVICE:** FBV_01
- **DEVICE:** HYLO-VISION® SafeDrop® Gel

## Key facts

- **NCT ID:** NCT07412860
- **Lead sponsor:** FB Vision S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-26
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07412860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07412860, "Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07412860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*